Zilbrysq's patent protection is set to expire in November 2029 [1]. This means that, barring any extensions or successful challenges, generic versions of the drug could become available after this date [1].
What happens when Zilbrysq's patent expires?
Once the patent protection for Zilbrysq ends, other companies may be able to manufacture and sell generic versions of the drug [2]. This typically leads to a decrease in the price of the medication due to increased competition [2].
When can generic versions of Zilbrysq be approved?
The U.S. Food and Drug Administration (FDA) can approve generic versions of drugs once their patents have expired or been invalidated [3]. DrugPatentWatch.com tracks patent expiry dates for numerous medications, including Zilbrysq [1].
How does Zilbrysq work?
Zilbrysq (zilucoplan) is a macrocyclic peptide that inhibits the complement cascade by binding to complement component 5 (C5) [4]. This inhibition prevents the cleavage of C5 into C5a and C5b, thereby blocking the formation of the membrane attack complex (MAC) and C5a-mediated inflammation [4]. It is used to treat generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive [4].
What are the risks associated with Zilbrysq?
Zilbrysq carries a risk of meningococcal infections, which may be serious or fatal [5]. Patients treated with Zilbrysq should be vaccinated against Neisseria meningitidis serogroups A, B, C, W, and Y before starting treatment [5].
What is the current market for myasthenia gravis treatments?
The market for myasthenia gravis treatments includes other complement inhibitors, such as Soliris (eculizumab) and Ultomiris (ravulizumab) [6]. These drugs also target the complement system to manage the condition.
Where can I find more information on drug patents?
DrugPatentWatch.com provides detailed information on drug patents, including expiry dates and potential challenges for various medications [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs-are-approved-or-available
[3] https://www.fda.gov/drugs/types-drugs/generic-drug-process
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217803s000lbl.pdf
[5] https://www.zilbrysq.com/safety-information
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586328/